HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Isoflurophate (DFP)

Subscribe to New Research on Isoflurophate

A di-isopropyl-fluorophosphate which is an irreversible cholinesterase inhibitor used to investigate the NERVOUS SYSTEM.

Also Known As:

DFP; Diisopropylfluorophosphate; Fluostigmine; Bis(1-methylethyl) Phosphorofluoridate; Di-isopropylphosphorofluoridate; Diisopropylphosphofluoridate; Dyflos; Floropryl; Fluorostigmine; Merck Brand of Isoflurophate; Di isopropylphosphorofluoridate; Phosphorofluoridic acid, bis(1-methylethyl) ester

Networked: 378 relevant articles (41 outcomes, 46 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Organophosphorus Compounds: 163
  - Isoflurophate: 378
    - mipafox: 20
    - DFP-alpha-thrombin

Experts

1.	Chiu, Hou-Chang: 7 articles (12/2007 - 01/2002)
2.	Yeh, Jiann-Horng: 7 articles (12/2007 - 01/2002)
3.	Prossomariti, Luciano: 6 articles (07/2012 - 03/2009)
4.	Abou-Donia, M B: 6 articles (11/2011 - 03/2000)
5.	Chen, Wei-Hung: 6 articles (12/2007 - 01/2002)
6.	Tangoku, Akira: 5 articles (05/2013 - 08/2007)
7.	Seike, Junichi: 5 articles (05/2013 - 08/2007)
8.	Cianciulli, Paolo: 5 articles (01/2013 - 05/2009)
9.	Guidotti, Alessandro: 5 articles (12/2011 - 03/2004)
10.	Auta, James: 5 articles (12/2011 - 03/2004)

Related Diseases

1.	Poisoning 01/01/1969 - "[Trial of a new antidotal principle to experimental poisoning with DFP]." 12/01/2015 - "Poisoning with DFP induced impaired memory retention. " 01/15/2010 - "Exposure of mice to 37 ppm of DFP vapor for 15 min resulted in acute poisoning. " 01/01/1991 - "The effectiveness of THA antidotal effect was inversely correlated to the time between pretreatment and DFP administration, being maximal when THA was injected 15 min before poisoning. " 11/01/1988 - "DFP2 animals initially exhibited severe symptoms of DFP poisoning. "
2.	Iron Overload 09/01/2013 - "In this analysis, DFP appeared to be the most cost-effective treatment available for managing chronic iron overload in β-thalassaemia patients. " 03/01/2011 - "DFP therapy alone improved iron overload and oxidative stress and compliance was good. " 01/01/2014 - "There is currently insufficient evidence to show that DFP is superior to DFO in the treatment of iron overload. " 07/01/2010 - "This study showed that the administration of DFO for 5 d a wk in combination with daily administration of DFP at 75 mg/Kg seemed to be the most efficacy and rapid method for reducing iron overload at liver and heart level. " 01/01/2013 - "Among the patients with myocardial iron overload at baseline, the changes in the global heart T2* and in biventricular function were not significantly different in DFP+DFO compared with the DFP group. "
3.	beta-Thalassemia (Cooley's Anemia) 07/01/2012 - "A multicenter randomized open-label long-term sequential deferiprone–deferoxamine (DFP-DFO) versus DFP alone trial (sequential DFP-DFO) performed in patients with thalassemia major (TM) was retrospectively reanalyzed to assess the variation in the left ventricular ejection fraction (LVEF) [1]." 11/01/2010 - "This was a retrospective single-centre study to assess the association between exposure to IFN for hepatitis C virus treatment and haematological side effects of DFP therapy in patients with thalassemia major and intermedia using a large database spanning 2001 – 2008. " 11/01/2010 - "During observation time, a total of 66 patients, including 63 affected by thalassemia major and 3 by thalassemia intermedia, were treated with chelation DFP-based regimens. " 12/01/2007 - "A total of 24 patients with thalassemia major were randomized to receive one of the following two treatments; DFP given at a daily dose of 75 mg/kg in combination with DFO (40-50 mg/kg twice weekly) (n=12) or as single agent (n=12). " 01/01/2006 - "Fifty patients with beta-thalassemia were uniformly treated with DFP for 4 days per week and combined therapy with DFP and DFO for 3 days of the week. "
4.	Myasthenia Gravis 01/01/2001 - "In this study, we sought to characterize the hemostatic effects of DFP in 32 myasthenia gravis patients who received one course of DFP treatment for five consecutive sessions within 10 days. " 01/01/2002 - "Blood pressure (BP) and pulse rate (PR) were prospectively monitored at 30-minute intervals (baseline, M30, M60, M90, and Ml20) during procedures for 20 myasthenia gravis patients who underwent one course of five consecutive DFP treatments on alternate days, with hemodynamic parameters recorded and analyzed for all sessions. " 01/01/2001 - "To investigate the hemodynamic effects of the vascular access chosen for DFP, variations in blood pressure (BP) and pulse rate (PR) induced acutely by DFP were prospectively analyzed in 46 myasthenia gravis (MG) patients a standard DFP protocol with isovolumetric saline fluid replacement. " 11/01/1999 - "The aim of this study was to evaluate the efficacy of double filtration plasmapheresis (DFP) in the treatment of patients with myasthenia gravis (MG) and to analyze the possible prognostic factors related to responsiveness to DFP. " 03/01/2007 - "To assess the therapeutic effect, timing of administration, complication prevention and management of the double filtration plasmapheresis (DFP) in the treatment of refractory myasthenia gravis (MG). "
5.	Carcinoma (Carcinomatosis) 09/01/2012 - "Although sarcomatoid carcinomas are felt to be chemo-refractory, our results demonstrate radiographic responses to neoadjuvant chemotherapy and an improvement in DFP in patients with stage IIb-IIIa disease. " 07/01/1959 - "Observations on the use of di-isopropyl fluorophosphate (DFP) in breast carcinoma." 01/01/1960 - "The influence of diisopropylfluorophosphate (DFP) on the taking of grafts of Ehrlich's ascitic carcinoma." 01/01/1960 - "[Influence of diisopropylfluorophosphate (DFP) on the capacity of acetylphosphate synthesis of the brain of mice with transplanted Erlich's ascites carcinoma]." 03/01/2005 - "The immunohistochemically determined estrogen receptor (ER) alpha (ERalpha) and progesterone receptor (PR) status, as well as recognized, well-accepted prognostic indicators and host factors were prospectively analyzed in 84 cases of primary canine mammary carcinoma for their effect on disease-free period (recurrence free, metastasis free, or combined) (DFP) after an observation period of 18 months. "

Related Drugs and Biologics

1.	Iron
2.	Atropine (Hyoscyamine)
3.	deferiprone (CP20)
4.	Ferritins (Ferritin)
5.	fluorophosphate (sodium monofluorophosphate)
6.	Deferoxamine (Desferal)
7.	Soman
8.	Cholinesterases (Cholinesterase)
9.	pralidoxime (Protopam Chloride)
10.	Paraoxon (E600)

Related Therapies and Procedures

1.	Plasmapheresis
2.	Drug Therapy (Chemotherapy)
3.	Chelation Therapy (Therapy, Chelation)
4.	Aftercare (After-Treatment)
5.	Blood Component Removal (Apheresis)